Product image of Havrix (Hepatitis A Virus (Inactivated), Algeldrate) supplied by GNH India

Havrix

Active Ingredient:
Hepatitis A Virus (Inactivated), Algeldrate
Origin:
EU

Havrix (Hepatitis A Virus (Inactivated), Algeldrate)

Havrix is an injectable vaccine containing inactivated hepatitis A virus (with algeldrate as an excipient). It is supplied as a sterile solution for intramuscular use, marketed in the European Union. The product is prescribed to stimulate active immunity against hepatitis A infection. The vaccine is administered as a single dose or as part of a two‑dose schedule, depending on the vaccination program, and is classified as a prescription‑only product.

Manufacturer / TM Owner

Glaxosmithkline Biologicals S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Havrix is indicated for the prevention of hepatitis A infection in individuals who have not been previously immunized.

  • Active immunization of adults and children aged 12 months and older.
  • Protection of travelers to regions with high hepatitis A endemicity.
  • Prevention of outbreaks in community settings such as schools or camps.
  • Immunization of persons with occupational exposure to hepatitis A virus, e.g., laboratory workers.

Side Effects

Following intramuscular injection, Havrix may cause transient local or systemic reactions; most are mild and resolve without intervention.

Common

  • Pain, redness, or swelling at the injection site.
  • Low‑grade fever.
  • Headache.
  • Fatigue or malaise.
  • Nausea.
  • Muscle aches.

Serious

  • Severe allergic reaction (anaphylaxis).
  • Guillain‑Barré syndrome (rare).
  • High fever.
  • Persistent joint pain.

Precautions & Warnings

Healthcare providers should assess individual risk factors and medical history before administering Havrix to ensure safe and effective vaccination.

  • Not recommended for persons with known severe allergy to any vaccine component.
  • Use with caution in individuals with a history of hypersensitivity to gelatin or egg proteins.
  • Delay vaccination in moderate or severe acute illness.
  • Consult a physician for pregnant or breastfeeding women; safety data are limited.
  • Post‑vaccination serology may be considered for immunocompromised patients.
  • Observe for at least 15 minutes after injection for immediate reactions.

Avoid Interactions

Havrix does not have many documented drug‑drug interactions, but certain conditions may influence its administration or immune response.

Avoid

  • Concomitant administration of other live vaccines within 4 weeks.
  • Use of immunoglobulin products within 2 weeks before or after vaccination (may reduce antibody response).

Use with caution

  • Immunosuppressive therapy (e.g., corticosteroids, chemotherapy) may diminish vaccine efficacy.
  • Chronic liver disease may require adjusted dosing schedule.
  • Antipyretics can be taken to manage mild fever or pain after vaccination.

Frequently Asked Questions

Havrix is approved for individuals 12 months of age and older, including children, adolescents, adults, and older adults.

Full protection is typically achieved with two doses administered six months apart; a single dose may be used for short‑term travel protection.

Safety data in pregnancy are limited; vaccination should be considered only if the potential benefit outweighs any theoretical risk. Breastfeeding is not a contraindication.

Common reactions include pain, redness, or swelling at the injection site, low‑grade fever, headache, fatigue, nausea, and muscle aches.

Severe allergic reactions such as anaphylaxis are rare but possible; individuals with a known severe allergy to any vaccine component should avoid the vaccine.

Live vaccines should be spaced at least four weeks apart from Havrix to avoid potential interference with immune response.

Administration of immunoglobulin within two weeks before or after Havrix may reduce the vaccine’s antibody response and should be avoided.

Immunosuppressive drugs such as corticosteroids or chemotherapy can diminish the immune response to Havrix, potentially requiring additional monitoring.

Yes, Havrix is commonly used to protect travelers to areas where hepatitis A is endemic, ideally administered at least two weeks before travel.

A high fever is a rare serious reaction; seek medical attention promptly if fever persists or is accompanied by severe symptoms.

Individuals with chronic liver disease may receive Havrix, but dosing schedules might be adjusted and close follow‑up is advised.

Immunity is generally long‑lasting, with protective antibodies persisting for at least 10‑20 years after the complete two‑dose series.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Hepatitis A Virus (Inactivated), Algeldrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT